Cytek Biosciences annual stock-based compensation
2020
2021
2022
2023
2024
2025
Cytek Biosciences Stock-Based Compensation Growth & History (CTKB)
Cytek Biosciences's stock-based compensation was $24.6M for fiscal 2025.
View full Cytek Biosciences company overviewCytek Biosciences annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $24.6M | −$2.3M | −8.43% |
| 2024 | 2024-12-31 | $26.8M | $4.8M | +21.77% |
| 2023 | 2023-12-31 | $22.0M | $5.5M | +32.86% |
| 2022 | 2022-12-31 | $16.6M | $10.0M | +151.97% |
| 2021 | 2021-12-31 | $6.6M | $6.0M | +977.91% |
| 2020 | 2020-12-31 | $611,000 | — | — |
Cytek Biosciences quarterly stock-based compensation
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.3M | −$1.5M | −21.37% |
| Q1 2026 | 2026-03-31 | $4.9M | −$1.8M | −26.68% |
| Q4 2025 | 2025-12-31 | $5.5M | −$1.5M | −21.08% |
| Q3 2025 | 2025-09-30 | $5.6M | −$1.4M | −20.06% |
| Q2 2025 | 2025-06-30 | $6.8M | −$362,000 | −5.06% |
| Q1 2025 | 2025-03-31 | $6.6M | $990,000 | +17.55% |
| Q4 2024 | 2024-12-31 | $7.0M | $1.3M | +23.53% |
| Q3 2024 | 2024-09-30 | $7.1M | $1.3M | +22.49% |
| Q2 2024 | 2024-06-30 | $7.2M | $1.2M | +20.77% |
| Q1 2024 | 2024-03-31 | $5.6M | $941,000 | +20.03% |
| Q4 2023 | 2023-12-31 | $5.7M | $1.2M | +26.97% |
| Q3 2023 | 2023-09-30 | $5.8M | $1.4M | +32.09% |
| Q2 2023 | 2023-06-30 | $5.9M | $2.0M | +50.53% |
| Q1 2023 | 2023-03-31 | $4.7M | $862,000 | +22.47% |
| Q4 2022 | 2022-12-31 | $4.5M | $1.5M | +48.44% |
| Q3 2022 | 2022-09-30 | $4.4M | $1.9M | +77.56% |
| Q2 2022 | 2022-06-30 | $3.9M | $3.3M | +489.81% |
| Q1 2022 | 2022-03-31 | $3.8M | $3.4M | +741.45% |
| Q4 2021 | 2021-12-31 | $3.0M | — | — |
| Q3 2021 | 2021-09-30 | $2.5M | $2.3M | +1848.41% |
| Q2 2021 | 2021-06-30 | $667,000 | $558,000 | +511.93% |
| Q1 2021 | 2021-03-31 | $456,000 | — | — |
| Q3 2020 | 2020-09-30 | $126,000 | — | — |
| Q2 2020 | 2020-06-30 | $109,000 | — | — |
Cytek Biosciences stock-based compensation trends
Over the last five fiscal years, Cytek Biosciences's stock-based compensation increased from $611,000 to $24.6M, a change of $24.0M. The latest reported quarter, Q2 2026, shows $5.3M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cytek Biosciences source filings ↗